Public Roundtable: The benefits of Public-Private Partnership generated RWE for vaccine monitoring - Lessons from DRIVE

As part of its Annual Forum, DRIVE will host a high-level Public Roundtable on 8 June from 14.00-15.30 CET.

The roundtable discussion will focus on how to ensure that the DRIVE projects’ results have a lasting impact on vaccine effectiveness policies in Europe. It will also cover the benefits and the value of public–private partnerships-generated Real World Evidence (RWE) for vaccine monitoring in Europe.

Moderated by Sue Saville, the roundtable will feature:

• Wolfgang Philipp, Acting Director, DG Health Emergency Preparedness and Response Authority (HERA), European Commission
• Dr Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, European Medicines Agency
• Hanna Nohynek, Chief Physician, Deputy Head Unit Infectious Disease Control & Vaccines, National Institute for Health and Welfare, THL, Finland
• Sibilia Quilici, Executive Director, Vaccines Europe

Introductory remarks by:

• Javier Diez Domingo, Director of the Vaccine Research Department, FISABIO-Public Health - DRIVE Public Coordinator
• Cédric Mahé, Head Modelling Epidemiology and Data science, Vaccines, Sanofi - DRIVE EFPIA Lead.

To register, please compile this form.

About DRIVE

Project DRIVE is a 5-year project funded under the Innovative Medicines Initiative (IMI) seeking to establish a sustainable study platform based on a sufficiently sized network to provide robust, high quality, brand-specific effectiveness estimates for all influenza vaccines used in the EU each season. In DRIVE, data from several independently operating national or regional study sites is analysed jointly to increase sample size for brand-specific influenza vaccine effectiveness estimates and account for EU diversity in vaccination recommendations and vaccines composition. Through a public-private partnership, DRIVE is expected to lead to enhanced dialogue between European stakeholders and thus facilitate the monitoring of influenza vaccine performance by public health institutes and allow manufacturers to fulfil the requirements of the European Medicines Agency (EMA).